多西他赛联合卡培他滨治疗转移性乳腺癌的临床疗效及其安全性  

Clinical efficacy and safety of docetaxel combined with capecitabine in the treatment of metastatic breast cancer

作　　者：丁勇[1] DING Yong(Changsha Central Hospital Affiliated to Nanhua University,Changsha 410004,China)

机构地区：[1]南华大学附属长沙中心医院,长沙市410004

出　　处：《临床合理用药杂志》2022年第18期38-41,共4页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的 观察多西他赛联合卡培他滨治疗转移性乳腺癌的临床疗效及其安全性。方法 选取2019年1月-2021年1月南华大学附属长沙中心医院收治的转移性乳腺癌患者76例,采用随机数字表法分为对照组与试验组,各38例。对照组予以多西他赛化疗,试验组予以多西他赛联合卡培他滨化疗。2组均连续治疗4个疗程。比较2组临床疗效,治疗前后血清癌胚抗原(CEA)和糖类抗原19-9(CA19-9)水平,无进展生存期,健康调查简表(SF-36)评分及不良反应。结果 试验组临床治疗总有效率为68.42%,高于对照组的44.74%(χ^(2)=4.338,P=0.037)。治疗后,2组血清CEA和CA19-9水平低于治疗前,且试验组低于对照组(P <0.01)。试验组无进展生存期长于对照组,SF-36评分高于对照组(P <0.05)。试验组不良反应总发生率为15.79%,与对照组的13.16%比较,差异无统计学意义(χ^(2)=0.106,P=0.744)。结论 多西他赛联合卡培他滨治疗转移性乳腺癌的临床疗效确切,可有效抑制癌细胞转移,延长无进展生存期,提高患者生活质量,且安全性较高。Objective To observe clinical efficacy and safety of docetaxel combined with capecitabine in the treatment of metastatic breast cancer. Methods A total of 76 cases of patients with metastatic breast cancer were selected from January 2019 to January 2021 in Changsha Central Hospital Affiliated to Nanhua University,which were divided into control group and experimental group by random number table method,with 38 cases in each group. The control group was given docetaxel chemotherapy,while the experimental group was given docetaxel combined with capecitabine chemotherapy. Both groups were treated continuously for 4 courses. Clinical efficacy,serum CEA and CA19-9 levels before and after treatment,progression-free survival,SF-36 score and incidence of adverse reactions were compared between the two groups. Results The total effective rate of the experimental group was 68. 42%,which was higher than 44. 74% in the control group( χ^(2)=4. 338,P = 0. 037). After treatment,the serum CEA and CA19-9 levels in the two groups were lower than those before treatment,and those in the experimental group were lower than control group( P < 0. 01). The progression-free survival time of the experimental group was longer than that of the control group,and the SF-36 score was higher than that of the control group( P < 0. 05). The total incidence of adverse reactions in the experimental group was 15. 79%,compared with 13. 16% in the control group,without significant difference( χ^(2)= 0. 106,P = 0. 744). Conclusion Docetaxel combined with capecitabine is effective in the treatment of metastatic breast cancer,which can effectively inhibit the metastasis of cancer cells,prolong the progression-free survival time,improve the quality of life of patients,and has high safety.

关 键 词：转移性乳腺癌 多西他赛 卡培他滨 治疗结果 药物不良反应 

分 类 号：R737.9[医药卫生—肿瘤]